# LoFly Bio

> Intelligence, research tools and discovery services for bispecific antibody development.

## Target Pairs
- [PD-1 × VEGF-A](/pair/pd1-vegf-a.html)
- [PD-L1 × VEGF-A](/pair/pdl1-vegf-a.html)
- [DLL3 × CD3](/pair/dll3-cd3.html)
- [EGFR × LGR5](/pair/egfr-lgr5.html)
- [EGFR × MET](/pair/egfr-met.html)

## Intelligence
- [Intelligence](/intelligence.html)
- [Target Pairs](/target-pairs.html)

## Market Report (BsAb-MR)
- [Bispecific Antibody Market Report](/report.html)
- [Executive Summary — Three Judgments](/report/ch01-executive-summary.html)
- [Market Overview — 538-Trial Census by TA](/report/ch02-market-overview.html)
- [Market Size — Scenarios to 2030E](/report/ch03-market-size.html)
- [Technology Landscape — Formats Decide the Reagent Stack](/report/ch04-technology.html)
- [TCE Deep Dive — CD3ε Standard Arm and Reagent Gaps](/report/ch05-tce.html)
- [Target Pairs — Five Golden Pairs, Scored](/report/ch06-target-pairs.html)
- [Autoimmune & Other TAs — Observation Sector](/report/ch07-autoimmune.html)
- [Clinical Pipeline — Readout Calendar and the Phase 2 Squeeze](/report/ch08-clinical-pipeline.html)
- [Deals & Financing — Where the Money Went](/report/ch09-deals.html)
- [Failures & Competition — Approval Is Not Winning](/report/ch10-failures.html)
- [Tools & Services — Commodity 6, Differentiated 1, White Space 1](/report/ch11-tools-services.html)
- [Methodology & Evidence Ledger](/report/ch12-methodology.html)

## Content (guides & application notes)
- [Experimental Design: CD16a 158V vs 158F Side-by-Side Comparison](/content/cd16a-158v-158f-comparison.html)
- [How to Select the Right CD16a (FcγRIIIa) Variant for FcγR Binding Studies](/content/cd16a-variant-guide.html)
- [CD47 / SIRPα Blocking Assay Design: Avoiding the Pitfalls That Invalidate Your Data](/content/cd47-sirpa-blocking.html)
- [Choosing CD3 Protein Formats for T-Cell Engager Development](/content/guide-cd3-formats.html)
- [CHO vs HEK293 for Early BsAb Expression](/content/guide-cho-hek293.html)
- [How to Design a DLL3 × CD3 Functional Screening Workflow](/content/guide-dll3-cd3-functional.html)
- [How to Validate Dual Binding for a Bispecific Antibody](/content/guide-dual-binding-validation.html)
- [Human vs Cynomolgus Antigen Selection](/content/guide-human-cyno-antigen.html)
- [How to Design an FcRn SPR Assay for pH-Dependent Antibody Half-Life Evaluation](/content/fcRn-spr-assay.html)
- [Step-by-Step: FcRn SPR Protocol with pH 6.0 / 7.4 Dual-Buffer Switch](/content/fcRn-spr-protocol.html)
- [IL-15 for NK Cell Expansion: Concentrations, Combinations, and Common Failures](/content/il15-nk-expansion.html)
- [PD-1 × VEGF-A Target Pair Landscape — What's Happening and Why It Matters](/content/gp01-pd1-vegf-landscape.html)
- [PD-L1 × VEGF-A Target Pair Landscape — Axis Validated, Format Unapproved](/content/gp02-pdl1-vegf-landscape.html)
- [DLL3 × CD3 Target Pair Landscape — The TCE Benchmark Pair](/content/gp03-dll3-cd3-landscape.html)
- [EGFR × LGR5 Target Pair Landscape — An Emerging Pair With a Real Reagent Gap](/content/gp04-egfr-lgr5-landscape.html)
- [EGFR × MET Target Pair Landscape — Approved Reference, Multi-Generational Pipeline](/content/gp05-egfr-met-landscape.html)
- [TIGIT / CD155 Matched Pair: Workflow and Optimization for BLI and SPR](/content/tigit-pair-guide.html)

## Hubs
- [CD16a Hub — FcγRIIIa Variants & ADCC Evaluation](/hub/cd16a.html)
- [CD47 / SIRPα Hub — Macrophage Checkpoint Discovery Tools](/hub/cd47-sirpa.html)
- [FcRn Hub — Antibody Half-Life & Fc Engineering](/hub/fcRn.html)
- [IL-15 Hub — NK Expansion & Cell Therapy Cytokines](/hub/il15.html)
- [TIGIT / CD155 Hub — Matched Pair for Checkpoint Screening](/hub/tigit-cd155.html)

## Protocols (draft — literature-based, pending wet-lab validation)
- [Protocol: CD16a SPR KD Measurement — 158V vs 158F Side by Side](/content/cd16a-spr-kd.html)
- [Protocol: CD47–SIRPα SPR Binding & Antibody Blocking](/content/cd47-sirpa-spr-blocking.html)
- [Protocol: IL-15 NK Expansion (PBMC-based, Research Grade)](/content/il15-nk-expansion-protocol.html)
- [Protocol: TIGIT–CD155 BLI Binding & Competition](/content/tigit-cd155-bli.html)

## Research Tools
- [FcRn Protein](/hero/fcrn.html)
- [CD16a (V158 & F158)](/hero/cd16a.html)
- [IL-15 (Animal-Free)](/hero/il15.html)
- [B7-H3 (4Ig)](/hero/b7h3.html)
- [TIGIT/CD155 Matched Pair](/pairs/tigit-cd155.html)
- [CD47/SIRPα Matched Pair](/pairs/cd47-sirpa.html)
- [Cytokine Bundle (IL-15/IL-21/IL-7)](/pairs/cell-therapy-cytokines.html)

## Tool Sets
- [Half-Life Starter Panel](/bundles/half-life-starter-panel.html)
- [Human/Cyno PK Translation Panel](/bundles/pk-translation-panel.html)
- [TIGIT/CD155 Discovery Pair](/bundles/tigit-cd155-discovery-pair.html)
- [CD47/SIRPα Functional Pair](/bundles/cd47-sirpa-functional-pair.html)
- [T/NK Expansion Cytokine Set](/bundles/tnk-expansion-cytokine-set.html)
- [CD19 CAR QC Set](/bundles/cd19-car-qc-set.html)
- [HSPC Core 3](/bundles/hspc-core-3.html)
- [TCE Dual-Arm Panel](/bundles/tce-dual-arm-panel.html)

## Services
- [BsAb Expression](/services/bsab-expression.html)
- [Dual Binding Characterization](/services/dual-binding.html)
- [Functional Screening](/services/functional-screening.html)

## Contact
- [Request Sample / Quote / Talk to a Scientist](/request)